These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17131241)

  • 1. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
    Westerfeld N; Pluschke G; Zurbriggen R
    Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptides delivered by immunostimulating reconstituted influenza virosomes.
    Westerfeld N; Zurbriggen R
    J Pept Sci; 2005 Nov; 11(11):707-12. PubMed ID: 16059967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
    Glück R; Moser C; Metcalfe IC
    Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza virosomes: a flu jab for malaria?
    Cavanagh DR; Remarque EJ; Sauerwein RW; Hermsen CC; Luty AJ
    Trends Parasitol; 2008 Sep; 24(9):382-5. PubMed ID: 18684667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The virosome concept for influenza vaccines.
    Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
    Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virosomes as a vaccine adjuvant and carrier system.
    Moser C; Amacker M; Zurbriggen R
    Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccines: the virosome concept.
    Wilschut J
    Immunol Lett; 2009 Feb; 122(2):118-21. PubMed ID: 19100779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
    BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
    Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virosomes in vaccine development.
    Huckriede A; Bungener L; Daemen T; Wilschut J
    Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro.
    Schumacher R; Amacker M; Neuhaus D; Rosenthal R; Groeper C; Heberer M; Spagnoli GC; Zurbriggen R; Adamina M
    Vaccine; 2005 Dec; 23(48-49):5572-82. PubMed ID: 16165256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems.
    Glück R; Metcalfe IC
    Vaccine; 2003 Jan; 21(7-8):611-5. PubMed ID: 12531327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular vaccines for malaria.
    Bruder JT; Angov E; Limbach KJ; Richie TL
    Hum Vaccin; 2010 Jan; 6(1):54-77. PubMed ID: 20061792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
    Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
    Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites.
    Tsuji M; Zavala F
    Mol Immunol; 2001 Dec; 38(6):433-42. PubMed ID: 11741693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
    Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
    Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.